Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial



Summary

The SWOG S1512 phase 2 trial investigated pembrolizumab (anti-PD-1 therapy) in patients with unresectable desmoplastic melanoma (DM), a rare and aggressive subtype. The study found pembrolizumab demonstrated a promising objective response rate (ORR) in DM patients. Importantly, the trial showed that a significant portion of patients experienced durable responses. While further research is needed, the results suggest that anti-PD-1 therapy may represent an effective treatment option for advanced DM, particularly given its historical resistance to traditional chemotherapy. The findings support considering immunotherapy as a first-line treatment strategy.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!